摘要
目的比较不同剂量阿托伐他汀用于急性脑梗死静脉溶栓治疗后的效果以及对症状性出血的影响。方法选取2017年4月-2019年6月东港市中心医院收治的急性脑梗死患者150例为研究对象,均接受静脉溶栓治疗,采取随机数字表法分为低剂量组、标准剂量组和高剂量组,每组50例。3组分别于静脉溶栓治疗后给予阿托伐他汀10、20、40 mg/d治疗,比较3组治疗总有效率、治疗前后超敏C反应蛋白(hs-CRP)水平、症状性出血发生率及不良反应总发生率。结果3组总有效率两两比较差异有统计学意义(P<0.05或P<0.01),低剂量组总有效率<标准剂量组<高剂量组。治疗3个月后,3组hs-CRP水平均较治疗降低,且治疗后hs-CRP水平两两比较差异有统计学意义(P<0.01)。高剂量组症状性出血率为2.0%,低于标准按剂量组的14.0%和低剂量组的22.0%(P<0.05或P<0.01)。3组不良反应总发生率比较差异无统计学意义(P>0.05)。结论高剂量(40 mg/d)阿托伐他汀用于急性脑梗死静脉溶栓后患者中疗效确切,可改善患者预后,不良反应少,值得临床推广应用。
Objective Compare the effects of different doses of atorvastatin after intravenous thrombolytic therapy for acute cerebral infarction and its effect on symptomatic hemorrhage.Methods 150 patients with acute cerebral infarction treated by Donggang City Central Hospital from April 2017 to June 2019 were treated with intravenous thrombolysis,and the patients were randomly divided into three groups:low-dose group,standard-dose group and high-dose group(n=50).Three groups were given atorvastatin 10,20,40 mg/d after intravenous thrombolysis.The total effective rate,the level of hs-CRP before and after treatment,the incidence of symptomatic bleeding and the total incidence of adverse reactions were compared among the three groups.Results There was a statistically significant difference in the total effective rate between the three groups(P<0.05 or P<0.01).The total effective rate in the low-dose group was less than the standard dose group and the high-dose group.After 3 months of treatment,the level of hs-CRP in the three groups was lower than that of the treatment,and there was a statistically significant difference in hs-CRP level after treatment(P<0.01).The symptomatic bleeding rate in the high-dose group was 2.0%,which was lower than the standard dose-based group of 14.0%and the low-dose group of 22.0%(P<0.05 or P<0.01).There was no significant difference in the total incidence of adverse reactions among the three groups(P>0.05).Conclusion High dose(40 mg/d)atorvastatin is effective in patients with acute cerebral infarction after intravenous thrombolysis.It can improve the prognosis of patients,with fewer adverse reactions.It is worthy of clinical application.
作者
刘晓华
LIU Xiaohua(Donggang City Central Hospital,Liaoning Province,Donggang 118300,China)
出处
《临床合理用药杂志》
2020年第20期6-8,共3页
Chinese Journal of Clinical Rational Drug Use
关键词
急性脑梗死
静脉溶栓
阿托伐他汀
高剂量
症状性出血
NIHSS评分
Acute cerebral infarction
Intravenous thrombolysis
Atorvastatin
High dose
Symptomatic hemorrhage
NIHSS score
